Loading company…
Regado Biosciences developed therapeutic agents for cardiovascular diseases, including novel anticoagulants.
Regado Biosciences focused on developing therapies for cardiovascular diseases, including anticoagulants intended to manage blood clotting. Founded in 2001 in the United States, it raised USD 43.00 mn through an IPO in August 2013, priced at USD 4 per share. Tobira Therapeutics acquired the company in May 2015.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in